RxDoctor Payments Data

Kerry Cadogan, MD

Internal Medicine · St Petersburg, FLNPI 1265743058

Payments from drug & device makers

$449in general payments, 2019–2025

Across 17 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$111
  • Pfizer$99
  • Teva Pharmaceuticals USA, Inc.$63
  • Lilly USA, LLC$62
  • Amgen$28
  • Cipher Pharmaceuticals US LLC$26
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$111
Pfizer5$99
Teva Pharmaceuticals USA, Inc.2$63
Lilly USA, LLC3$62
Amgen2$28
Cipher Pharmaceuticals US LLC1$26
Exact Sciences1$23
Heartflow, Inc.1$20
Sumitomo Pharma America, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$449 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$413,356
Medicare patients
515
Services billed
3,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban761$219,028
OzempicSemaglutide42$43,425
JardianceEmpagliflozin131$38,688
XifaxanRifaximin13$38,669
RexultiBrexpiprazole54$38,003
ProcritEpoetin Alfa22$33,173
TrulicityDulaglutide53$32,337
Breo ElliptaFluticasone/Vilanterol77$29,855
ZenpepLipase/Protease/Amylase23$29,718
LinzessLinaclotide52$28,507
IsentressRaltegravir Potassium25$28,046
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$26,728
TeflaroCeftaroline Fosamil Acetate71$24,009
VraylarCariprazine Hcl36$23,925
SantylCollagenase Clostridium Hist.56$21,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$99$230,372774 claims
Lilly USA, LLCTrulicity$62$32,33753 claims
Sumitomo Pharma America, Inc.Gemtesa$16$14,30960 claims
AmgenEpogen$28$9,92214 claims
AstraZenecaBrilinta$111$8,26937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →